Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies
BioStem provides a business update and highlights recent accomplishments
Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million
National Pricing for Amniowrap2™ effective January 1st in all 50 states and territories
POMPANO BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- . (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced wound care, today highlights its 2023 accomplishments and provides a business update.
BioStem Technologies CEO, Jason Matuszewski, said, “2023 was a year of tremendous growth, progress and achievement for BioStem. This growth is primarily attributed to the successful launch of Amniowrap2™, our innovative placental-derived allograft product designed to address a broad spectrum of wound appl